CClinicalTrials.gg
RecruitingNCT07557628GLIPIDUpdated Sep 29, 2026

Study of the Hypothalamic Microglial Response as a Function of a Meal's Lipid Content in Humans. A Single-center Prospective Cohort Study in Healthy Male Subjects

An observational study in Pathophysiology, sponsored by Centre Hospitalier Universitaire Dijon. Recruiting at 1 site in France. Open to male participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Centre Hospitalier Universitaire Dijon · Observational

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Sep 29, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
20 Years and older
Sex
Male
01

Study summary

Obesity and its complications represent a growing public health problem in our society. A better understanding of the biological mechanisms involved in regulating food intake-and, more broadly, energy metabolism-should lead to improved management of this condition.

Recent studies have shown that eating a single meal can rapidly trigger the activation of the immune system. This leads to a postprandial, systemic, and transient inflammatory response (Emerson SR, Adv Nutr 2017). It is found in both healthy and obese individuals. It has also been observed in rodents, enabling preclinical studies to better understand the phenomenon. This postprandial inflammation is characterized by the activation of macrophages in the gastrointestinal tract and by elevated levels of circulating pro-inflammatory markers. At the cellular level, nutrients activate an intracellular molecular sensor called the inflammasome, which is a multiprotein complex formed by the oligomerization of proteins including NLRP3 (Nod-like receptors pyrin domain-containing 3) and ASC (Apoptosis-associated Speck-like protein containing a CARD domain). This sensor activates caspase 1, an enzyme that converts pro-interleukin 1β (pro-IL-1β) into its mature and active form, IL-1β. This molecular mechanism converts the nutritional signal into an immune response.

Under physiological conditions, this acute response appears to have beneficial effects on the body. Indeed, it plays a positive role in blood glucose control by stimulating insulin secretion and glucose utilization (Dror, Nat Immunol 2017). However, in the context of chronic overeating and excessive consumption of saturated fats and simple sugars, this systemic inflammation becomes harmful, promoting adipocyte hypertrophy, insulin resistance, hepatic steatosis, and vascular damage (Hotamisligil, Nature 2017).

In mice, our team recently demonstrated the existence of a postprandial inflammatory response in the central nervous system (Cansell, Glia 2021). This response occurs specifically in the hypothalamus, a brain structure involved in regulating food intake and controlling energy metabolism. It is characterized by microglial reactivity visible as early as 3 hours after the start of the postprandial phase. This postprandial microglial activation occurs after the ingestion of a high-fat meal, whereas it is rarely or never observed after the ingestion of a standard balanced meal. It is characterized by a morphological change in hypothalamic microglia, including an increase in the length of microglial processes and their branching. This gliosis is associated with increased expression of IL-1β in microglial cells. Thus, the postprandial gliosis observed 3 hours after a high-fat meal is inflammatory. Using a targeted genetic approach that allows for the ablation of the inflammasome in microglial cells, the team demonstrates that postprandial gliosis exerts a satiating effect, limiting subsequent food intake following a high-calorie, high-fat meal. Thus, microglial inflammation appears to be an additional component in the body's arsenal of adaptive homeostatic responses aimed at limiting energy intake.

Our clinical project will involve translating our basic findings in mice to humans. This will involve investigating postprandial hypothalamic gliosis in the human brain following a standard meal or a high-fat meal. The initial studies will be conducted exclusively in healthy male subjects to avoid the influence of the hormonal cycle on the hypothalamic response. The impact of physiological aging on the hypothalamic microglial inflammatory response will also be taken into account.

02

Conditions studied

  • Pathophysiology
03

In context

Lead sponsor

Centre Hospitalier Universitaire Dijon is the lead sponsor of 495 studies on the registry; 105 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy male volunteers

Inclusion criteria

  • A person who has given oral consent
  • Male
  • Body Mass Index (BMI) between 18.5 and 30 kg/m²
  • Age ≥ 20 years

Exclusion criteria

Exclusion Criteria:

  • A person subject to a measure of legal protection (guardianship, tutorship)
  • A person subject to a judicial protective measure
  • A person who is not enrolled in or eligible for a social security program
  • Subject does not speak French
  • Subjects with a pacemaker or any other contraindication to MRI
  • Subjects with type 1 or type 2 diabetes
  • Subjects with a chronic inflammatory condition
  • Subjects with a neuropsychiatric condition
  • Subjects taking anti-inflammatory medication or medication that affects the central nervous system
  • Known hypersensitivity to foods provided during the study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Male subjects

    Healthy volunteers to study the biological mechanisms that control food intake and energy metabolism

    Biological: Blood sample · Procedure: Brain MRI without contrast, performed on an empty stomach and after a meal · Other: Questionnaires · Other: Bioelectrical impedance analysis

Interventions

  • BiologicalBlood sample

    Hormone and metabolic tests (insulin, IGF-1, leptin, blood glucose, ghrelin)

  • ProcedureBrain MRI without contrast, performed on an empty stomach and after a meal

    Measurement of the T1 and T2 relaxation times in the hypothalamic region

  • OtherQuestionnaires

    Eating habits and preferences

  • OtherBioelectrical impedance analysis

    Measurements of lean body mass, fat mass, body water and bone mass

06

What researchers measure

Primary outcomes

  1. The difference in hypothalamic MRI signal intensity between the baseline state and the postprandial state observed after a balanced meal and after a high-fat meal for each subject.

    Measurement of hypothalamic T2 relaxation time

    Time frame: 2 days

07

Study locations

1 of 1 sites recruiting
08

Updates

1 registry update since Sep 25, 2026
Status
Not yet recruiting→Recruiting
changed Sep 29, 2026
Sites
Chu Dijon Bourgogne is now Recruiting
Sep 29, 2026
Start date
May 2026→Sep 5, 2026 (actual)
Sep 29, 2026
Primary completion
May 2028→Sep 2028
Sep 29, 2026
Study completion
May 2028→Sep 2028
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Not yet recruiting→Recruiting
    Chu Dijon Bourgogne is now Recruiting
    Start date May 2026→Sep 5, 2026 (now actual)
    Primary completion May 2028→Sep 2028
    Study completion May 2028→Sep 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07557628
Lead sponsor
Centre Hospitalier Universitaire Dijon
Responsible party
Sponsor
First posted
Apr 29, 2026
Start date
Sep 5, 2026
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Sep 29, 2026

Study contacts

Vincent SCHNEIDER
Contact
vincent.schneider@chu-dijon.fr
03 80 29 30 89 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion